Wealthfront Advisers’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.6M | Sell |
22,226
-11,629
| -34% | -$4.31M | 0.02% | 329 |
|
|
2026
Q1 | $9.91M | Sell |
33,855
-10,217
| -23% | -$3.36M | 0.02% | 272 |
|
|
2025
Q4 | $15.4M | Buy |
44,072
+9,030
| +26% | +$3.05M | 0.03% | 168 |
|
|
2025
Q3 | $11.3M | Buy |
35,042
+19,292
| +122% | +$6M | 0.03% | 219 |
|
|
2025
Q2 | $6.13M | Buy |
15,750
+2,042
| +15% | +$821K | 0.02% | 336 |
|
|
2025
Q1 | $5.96M | Buy |
13,708
+7,400
| +117% | +$2.97M | 0.02% | 316 |
|
|
2024
Q4 | $2.33M | Sell |
6,308
-7,006
| -53% | -$2.93M | 0.01% | 493 |
|
|
2024
Q3 | $6.92M | Sell |
13,314
-941
| -7% | -$503K | 0.02% | 236 |
|
|
2024
Q2 | $7.72M | Buy |
14,255
+254
| +2% | +$134K | 0.03% | 185 |
|
|
2024
Q1 | $7.26M | Sell |
14,001
-400
| -3% | -$199K | 0.03% | 189 |
|
|
2023
Q4 | $6.79M | Buy |
14,401
+3,345
| +30% | +$1.55M | 0.03% | 184 |
|
|
2023
Q3 | $4.81M | Sell |
11,056
-1,224
| -10% | -$555K | 0.02% | 218 |
|
|
2023
Q2 | $5.46M | Sell |
12,280
-4,144
| -25% | -$1.91M | 0.02% | 199 |
|
|
2023
Q1 | $7.55M | Sell |
16,424
-6,490
| -28% | -$3.09M | 0.03% | 150 |
|
|
2022
Q4 | $11.8M | Buy |
22,914
+1,740
| +8% | +$883K | 0.06% | 93 |
|
|
2022
Q3 | $9.62M | Sell |
21,174
-736
| -3% | -$352K | 0.05% | 97 |
|
|
2022
Q2 | $10.6M | Buy |
21,910
+2,642
| +14% | +$1.31M | 0.05% | 92 |
|
|
2022
Q1 | $9.46M | Buy |
19,268
+5,340
| +38% | +$2.44M | 0.04% | 105 |
|
|
2021
Q4 | $6.46M | Buy |
13,928
+46
| +0.3% | +$19.4K | 0.03% | 155 |
|
|
2021
Q3 | $5.17M | Buy |
13,882
+6,476
| +87% | +$2.46M | 0.02% | 158 |
|
|
2021
Q2 | $2.83M | Buy |
7,406
+1,153
| +18% | +$441K | 0.01% | 237 |
|
|
2021
Q1 | $2.25M | Buy |
6,253
+1,004
| +19% | +$323K | 0.01% | 239 |
|
|
2020
Q4 | $1.69M | Buy |
5,249
+435
| +9% | +$133K | 0.01% | 264 |
|
|
2020
Q3 | $1.29M | Buy |
4,814
+39
| +0.8% | +$10.5K | 0.01% | 273 |
|
|
2020
Q2 | $1.26M | Sell |
4,775
-523
| -10% | -$140K | 0.01% | 261 |
|
|
2020
Q1 | $1.2M | Sell |
5,298
-1,195
| -18% | -$326K | 0.01% | 235 |
|
|
2019
Q4 | $1.96M | Buy |
6,493
+614
| +10% | +$169K | 0.01% | 183 |
|
|
2019
Q3 | $1.41M | Sell |
5,879
-1,196
| -17% | -$328K | 0.01% | 225 |
|
|
2019
Q2 | $2M | Sell |
7,075
-23
| -0.3% | -$6.28K | 0.02% | 156 |
|
|
2019
Q1 | $2.04M | Buy |
7,098
+1,314
| +23% | +$380K | 0.02% | 143 |
|
|
2018
Q4 | $1.52M | Buy |
+5,784
| New | +$1.59M | 0.02% | 169 |
|
Other funds holding ELV
Wealthfront Advisers's ELV Position: Q2 2026 in Review
Wealthfront Advisers reduced its Elevance Health (ELV) stake by 34% in Q2 2026, selling an estimated $4.31M and leaving 22,226 shares worth $8.6M. The position accounts for 0.02% of the portfolio, ranked #329.
Wealthfront Advisers first reported a position in ELV in Q4 2018 and has held it in 31 quarters since. The position peaked at $15.4M in Q4 2025. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Wealthfront Advisers held 22,226 shares of Elevance Health worth $8.6M as of Q2 2026.
- Wealthfront Advisers sold 11,629 Elevance Health shares in Q2 2026, an estimated $4.31M.
- Elevance Health made up 0.02% of Wealthfront Advisers's portfolio in Q2 2026, its #329 holding.
- Wealthfront Advisers first reported a position in Elevance Health in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Elevance Health position peaked at $15.4M in Q4 2025.
- 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.